Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.63 -0.8%	$11.30	$8.04 ▼ $45.00	$342.54M	2.36	446,967 shs	1.00 million shs
ATYR Atyr PHARMA	$4.43 +4.0%	$3.28	$1.42 ▼ $4.66	$394.29M	0.79	945,005 shs	1.72 million shs
ITOS iTeos Therapeutics	$9.98 -0.5%	$6.99	$4.80 ▼ $18.13	$381.98M	1.39	641,808 shs	1.60 million shs
SNTI Senti Biosciences	$3.06 -1.6%	$3.39	$1.52 ▼ $16.94	$79.81M	2.31	802,748 shs	8,750 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	0.00%	+3.52%	-1.56%	-19.45%	-67.46%
ATYR Atyr PHARMA	0.00%	+18.13%	+23.06%	+34.24%	+442,999,900.00%
ITOS iTeos Therapeutics	0.00%	+16.59%	+28.44%	+42.78%	-40.38%
SNTI Senti Biosciences	0.00%	-4.38%	-7.83%	+6.99%	+2.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.8542 of 5 stars	4.6	0.0	2.6	2.5	0.6
ATYR Atyr PHARMA	2.7731 of 5 stars	3.6	1.0	3.4	3.3	0.6
ITOS iTeos Therapeutics	3.3107 of 5 stars	4.1	2.0	2.9	3.3	0.6
SNTI Senti Biosciences	2.8105 of 5 stars	3.5	5.0	1.8	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.11	Buy	$53.50	323.59% Upside
ATYR Atyr PHARMA	3.14	Buy	$18.60	319.86% Upside
ITOS iTeos Therapeutics	2.14	Hold	$15.86	58.89% Upside
SNTI Senti Biosciences	3.00	Buy	$12.00	292.16% Upside

Current Analyst Ratings Breakdown

Latest SNTI, ATYR, ARCT, and ITOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	ARCT Arcturus Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Outperform	$32.00
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/19/2025	ATYR Atyr PHARMA	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00 ➝ $35.00
5/14/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $13.00
5/14/2025	ITOS iTeos Therapeutics	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$12.00
5/14/2025	ITOS iTeos Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$16.00 ➝ $12.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/14/2025	ITOS iTeos Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/14/2025	ITOS iTeos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
5/14/2025	ITOS iTeos Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$47.00 ➝ $9.00

(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$131.27M	2.61	N/A	N/A	$10.42 per share	1.21
ATYR Atyr PHARMA	$235K	1,677.82	N/A	N/A	$1.54 per share	2.88
ITOS iTeos Therapeutics	$35M	10.91	N/A	N/A	$16.08 per share	0.62
SNTI Senti Biosciences	$2.56M	31.17	N/A	N/A	$15.02 per share	0.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$29.73M	-$2.53	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	8/4/2025 (Estimated)
ATYR Atyr PHARMA	-$50.39M	-$0.81	N/A	N/A	N/A	N/A	-79.44%	-59.16%	8/12/2025 (Estimated)
ITOS iTeos Therapeutics	-$112.64M	-$3.04	N/A	N/A	N/A	N/A	-20.11%	-17.50%	8/14/2025 (Estimated)
SNTI Senti Biosciences	-$71.06M	-$10.84	N/A	N/A	N/A	N/A	-154.84%	-77.42%	8/12/2025 (Estimated)

Latest SNTI, ATYR, ARCT, and ITOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/7/2025	Q1 2025	ATYR Atyr PHARMA	-$0.19	-$0.17	+$0.02	-$0.17	N/A	N/A
5/6/2025	Q1 2025	SNTI Senti Biosciences	-$0.56	-$1.41	-$0.85	-$1.41	$1.30 million	$1.30 million
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A
3/20/2025	Q4 2024	SNTI Senti Biosciences	-$3.13	-$0.67	+$2.46	-$0.67	$2.80 million	$5.86 million
3/13/2025	Q4 2024	ATYR Atyr PHARMA	-$0.23	-$0.18	+$0.05	-$0.18	$0.02 million	N/A
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million
3/5/2025	Q4 2024	ITOS iTeos Therapeutics	-$1.14	-$1.01	+$0.13	-$1.01	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	5.66%	N/A	N/A	N/A
ATYR Atyr PHARMA	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	4.76	4.76
ATYR Atyr PHARMA	0.02	5.41	5.41
ITOS iTeos Therapeutics	N/A	14.80	14.80
SNTI Senti Biosciences	N/A	1.92	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
ATYR Atyr PHARMA	61.72%
ITOS iTeos Therapeutics	97.16%
SNTI Senti Biosciences	25.73%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
ATYR Atyr PHARMA	3.70%
ITOS iTeos Therapeutics	12.50%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
ATYR Atyr PHARMA	53	89.00 million	80.84 million	Optionable
ITOS iTeos Therapeutics	90	38.27 million	31.97 million	Optionable
SNTI Senti Biosciences	4	26.08 million	4.30 million	Not Optionable

SNTI, ATYR, ARCT, and ITOS Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

June 1 at 10:00 AM | prnewswire.com

Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update

June 1 at 5:49 AM | marketbeat.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation into Senti Biosciences Inc

May 30 at 1:15 PM | accessnewswire.com

Senti Biosciences (NASDAQ:SNTI) Stock Price Down 3% - Time to Sell?

May 30 at 3:39 AM | marketbeat.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation Into Senti Biosciences Inc

May 29, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Connect

May 29, 2025 | accessnewswire.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of an Investigation Into Senti Biosciences Inc

May 28, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Shareholders to Reach Out

May 28, 2025 | accessnewswire.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Informs Shareholders of an Investigation into Senti Biosciences Inc

May 27, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

May 27, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Shareholders to Learn More About the Investigation

May 27, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Senti Biosciences, Inc. (SNTI) and Encourages Investors to Learn More About the Investigation

May 26, 2025 | accessnewswire.com

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 25, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

May 24, 2025 | accessnewswire.com

Senti Biosciences Receives Additional $1 Million from CIRM to Support Clinical Development of SENTI-202 Cell Therapy

May 23, 2025 | nasdaq.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc

May 23, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Investors to Connect

May 23, 2025 | accessnewswire.com

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22, 2025 | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Stockholders to Inquire about Securities Investigation

May 22, 2025 | accessnewswire.com

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

May 22, 2025 | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation

May 21, 2025 | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, ATYR, ARCT, and ITOS Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$12.63 -0.10 (-0.79%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$12.53 -0.10 (-0.79%)

As of 04:01 AM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Atyr PHARMA NASDAQ:ATYR

$4.43 +0.17 (+3.99%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$4.47 +0.04 (+0.90%)

As of 03:59 AM Eastern

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

iTeos Therapeutics NASDAQ:ITOS

$9.98 -0.05 (-0.50%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$10.02 +0.04 (+0.40%)

As of 04:00 AM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Senti Biosciences NASDAQ:SNTI

$3.06 -0.05 (-1.61%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.14 +0.08 (+2.61%)

As of 03:59 AM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time